RESEARCH_Transform

New from the World Conference on Lung Cancer: Positive clinical trial results for ALK+ NSCLC patients who had been treated with and experienced disease progression on their most recent crizotinib therapy.

Read the article: http://www.businesswire.com/news/home/20161207005305/en/ARIAD%E2%80%99s-Investigational-Medicine-Brigatinib-Demonstrated%C2%A015.6-Month-Systemic